JANUX THERAPEUTICS INC (JANX) Stock Fundamental Analysis
USA - NASDAQ:JANX - US47103J1051 - Common Stock
28.71 USD
-0.31 (-1.07%)
Overall JANX gets a fundamental rating of 4 out of 10. We evaluated JANX against 533 industry peers in the Biotechnology industry. While JANX has a great health rating, there are worries on its profitability. JANX is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
JANX had negative earnings in the past year.
JANX had a negative operating cash flow in the past year.
In the past 5 years JANX always reported negative net income.
JANX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
With an excellent Return On Assets value of -9.94%, JANX belongs to the best of the industry, outperforming 84.05% of the companies in the same industry.
JANX has a better Return On Equity (-10.43%) than 88.18% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -9.94% | ||
| ROE | -10.43% | ||
| ROIC | N/A |
ROA(3y)-13.05%
ROA(5y)-17.92%
ROE(3y)-14.45%
ROE(5y)-29.83%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for JANX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
JANX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for JANX has been increased compared to 1 year ago.
Compared to 5 years ago, JANX has more shares outstanding
There is no outstanding debt for JANX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
JANX has an Altman-Z score of 21.95. This indicates that JANX is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 21.95, JANX belongs to the best of the industry, outperforming 91.56% of the companies in the same industry.
JANX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 21.95 |
ROIC/WACCN/A
WACC8.76%
2.3 Liquidity
A Current Ratio of 35.86 indicates that JANX has no problem at all paying its short term obligations.
With an excellent Current ratio value of 35.86, JANX belongs to the best of the industry, outperforming 98.87% of the companies in the same industry.
JANX has a Quick Ratio of 35.86. This indicates that JANX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 35.86, JANX belongs to the top of the industry, outperforming 98.87% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 35.86 | ||
| Quick Ratio | 35.86 |
3. Growth
3.1 Past
JANX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -43.59%.
Looking at the last year, JANX shows a very negative growth in Revenue. The Revenue has decreased by -23.37% in the last year.
Measured over the past years, JANX shows a very strong growth in Revenue. The Revenue has been growing by 42.75% on average per year.
EPS 1Y (TTM)-43.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%23.53%
Revenue 1Y (TTM)-23.37%
Revenue growth 3Y42.75%
Revenue growth 5YN/A
Sales Q2Q%2177.9%
3.2 Future
The Earnings Per Share is expected to decrease by -17.34% on average over the next years. This is quite bad
JANX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 77.61% yearly.
EPS Next Y-82.3%
EPS Next 2Y-55.29%
EPS Next 3Y-43.93%
EPS Next 5Y-17.34%
Revenue Next Year-74.1%
Revenue Next 2Y-29.86%
Revenue Next 3Y-22.35%
Revenue Next 5Y77.61%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for JANX. In the last year negative earnings were reported.
Also next year JANX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
JANX's earnings are expected to decrease with -43.93% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-55.29%
EPS Next 3Y-43.93%
5. Dividend
5.1 Amount
JANX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:JANX (11/19/2025, 2:58:08 PM)
28.71
-0.31 (-1.07%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners107.51%
Inst Owner Change1.59%
Ins Owners1.45%
Ins Owner Change2.33%
Market Cap1.73B
Revenue(TTM)10.00M
Net Income(TTM)-101.89M
Analysts86.67
Price Target81.35 (183.35%)
Short Float %12.73%
Short Ratio7
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)11.26%
Min EPS beat(2)-15.55%
Max EPS beat(2)38.06%
EPS beat(4)3
Avg EPS beat(4)12.66%
Min EPS beat(4)-15.55%
Max EPS beat(4)38.06%
EPS beat(8)6
Avg EPS beat(8)14.06%
EPS beat(12)10
Avg EPS beat(12)18.21%
EPS beat(16)12
Avg EPS beat(16)14.95%
Revenue beat(2)1
Avg Revenue beat(2)67.39%
Min Revenue beat(2)-100%
Max Revenue beat(2)234.78%
Revenue beat(4)1
Avg Revenue beat(4)-16.3%
Min Revenue beat(4)-100%
Max Revenue beat(4)234.78%
Revenue beat(8)4
Avg Revenue beat(8)148.09%
Revenue beat(12)8
Avg Revenue beat(12)153.87%
Revenue beat(16)12
Avg Revenue beat(16)157.29%
PT rev (1m)1.72%
PT rev (3m)-2.19%
EPS NQ rev (1m)3.22%
EPS NQ rev (3m)-14.91%
EPS NY rev (1m)-0.56%
EPS NY rev (3m)-11.68%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-4.76%
Revenue NY rev (1m)0.34%
Revenue NY rev (3m)616.67%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 172.52 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.77 | ||
| P/tB | 1.77 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.68
EYN/A
EPS(NY)-3.09
Fwd EYN/A
FCF(TTM)-1.19
FCFYN/A
OCF(TTM)-1.17
OCFYN/A
SpS0.17
BVpS16.25
TBVpS16.25
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -9.94% | ||
| ROE | -10.43% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-13.05%
ROA(5y)-17.92%
ROE(3y)-14.45%
ROE(5y)-29.83%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.01
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 47.23% | ||
| Cap/Sales | 9.79% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 35.86 | ||
| Quick Ratio | 35.86 | ||
| Altman-Z | 21.95 |
F-Score2
WACC8.76%
ROIC/WACCN/A
Cap/Depr(3y)293.31%
Cap/Depr(5y)445.07%
Cap/Sales(3y)33.73%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-43.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%23.53%
EPS Next Y-82.3%
EPS Next 2Y-55.29%
EPS Next 3Y-43.93%
EPS Next 5Y-17.34%
Revenue 1Y (TTM)-23.37%
Revenue growth 3Y42.75%
Revenue growth 5YN/A
Sales Q2Q%2177.9%
Revenue Next Year-74.1%
Revenue Next 2Y-29.86%
Revenue Next 3Y-22.35%
Revenue Next 5Y77.61%
EBIT growth 1Y-67.85%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-76.01%
EBIT Next 3Y-39.39%
EBIT Next 5Y-20.63%
FCF growth 1Y-27.54%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-33.93%
OCF growth 3YN/A
OCF growth 5YN/A
JANUX THERAPEUTICS INC / JANX FAQ
What is the fundamental rating for JANX stock?
ChartMill assigns a fundamental rating of 4 / 10 to JANX.
What is the valuation status of JANUX THERAPEUTICS INC (JANX) stock?
ChartMill assigns a valuation rating of 0 / 10 to JANUX THERAPEUTICS INC (JANX). This can be considered as Overvalued.
Can you provide the profitability details for JANUX THERAPEUTICS INC?
JANUX THERAPEUTICS INC (JANX) has a profitability rating of 2 / 10.